About the Event
Kineta (NASDAQ: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies. Their novel drug programs are focused on addressing and correcting immuno-suppression, exhausted T-cells, and poor tumor immune response.
Kineta entered into a clinical trial collaboration and supply agreement with Merck to evaluate KVA12123, a monoclonal antibody that binds to VISTA, a key driver of immunosuppression.
The trial will look at KVA12123 alone and in combination with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). It is targeting several cancer types with an estimated total addressable market eclipsing $25B.
Join this webinar with Kineta CEO, Shawn Iadonato and John Vandermosten, Senior Biotechnology Analyst, Zacks Investment Research, to learn more about their partnership with Merck and what it could mean for the future of cancer therapy.